Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma
OncoImmune raises $56M series B
OncoImmune Inc. raised $56 million in a series B round co-led by HM Capital and an undisclosed investor. Also participating were fellow new investors GBA Fund and GF Xinde, and existing investors 3E Bioventures Capital and Kaitai Capital. Lead candidate CD24Fc is in Phase III trials in severe and critical COVID-19 patients and in leukemia patients prone to acute graft-versus-host disease following allogeneic hematopoietic stem cell transplant.
Forbion leads $35M series B for Inversago
Inversago Pharma Inc. raised $35 million in a series B led by Forbion, with participation from Fonds de solidarité FTQ and existing investors Genesys, JDRF T1D Fund, Amorchem, Anges Québec Capital, adMare BioInnovations and undisclosed angel investors. The funds will support clinical proof-of-concept testing for INV-101, which targets CB1, in development for metabolic and fibrotic diseases. ...